Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VentriPoint DiagnosticsVPTDF 3-Year EPS without NRI Growth Rate is 12.60% as of Dec. 2025, which is 28% below its 10-year median of 17.60. The stock has 4 warning signs investors should review. Among 658 Medical Devices & Instruments companies, VentriPoint Diagnostics ranks better than 55.93% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 12.60% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -0.60% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 15.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of VentriPoint Diagnostics was 62.10% per year. The lowest was -114.00% per year. And the median was 17.60% per year.
VentriPoint Diagnostics (OTCPK:VPTDF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
VentriPoint Diagnostics 3-Year EPS without NRI Growth Rate Related Terms
VPTDF vs ABT, SYK, MDT: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, VentriPoint Diagnostics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VentriPoint Diagnostics 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, VentriPoint Diagnostics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where VentriPoint Diagnostics's 3-Year EPS without NRI Growth Rate falls into.
VentriPoint Diagnostics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 12.60% mean?
VentriPoint Diagnostics (VPTDF) has a 3-Year EPS without NRI Growth Rate of 12.60% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for VentriPoint Diagnostics and its competitors. This is 28% below median its historical median of 17.60. According to the industry distribution chart, VentriPoint Diagnostics ranks #290 out of 658 companies in the Medical Devices & Instruments industry, placing it in the top 44.1%.
Is VentriPoint Diagnostics' 3-Year EPS without NRI Growth Rate too high?
VentriPoint Diagnostics' current 3-Year EPS without NRI Growth Rate of 12.60% is 28% below median its 10-year median of 17.60. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.05. VentriPoint Diagnostics' value of 12.60% is 56.5% above this industry median. Based on the distribution chart, VentriPoint Diagnostics ranks #290 out of 658 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does VentriPoint Diagnostics' 3-Year EPS without NRI Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, VentriPoint Diagnostics ranks #290 out of 658 companies for 3-Year EPS without NRI Growth Rate. This puts VentriPoint Diagnostics in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 8.05. VentriPoint Diagnostics' value of 12.60% is 56.5% above this benchmark. While the company's 10-year median is 17.60 vs. the industry median of 8.05, VentriPoint Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VentriPoint Diagnostics's current 3-Year EPS without NRI Growth Rate of 12.60% is 56.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for VentriPoint Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VentriPoint Diagnostics's current 3-Year EPS without NRI Growth Rate is 12.60%, which is 28% below median its own 10-year median of 17.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VentriPoint Diagnostics stock overvalued right now?
VentriPoint Diagnostics (VPTDF) has a current 3-Year EPS without NRI Growth Rate of 12.60%. The current 3-Year EPS without NRI Growth Rate is 12.60%, which is 28% below median its 10-year median of 17.60 and 56.5% above the Medical Devices & Instruments industry median of 8.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For VentriPoint Diagnostics (VPTDF), the current 3-Year EPS without NRI Growth Rate is 12.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VPTDF has been successfully added to your 
